(Q44114890)

29 November 2017

title

Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study (English)

1 reference

29 November 2017

2

R R Recker

0 references

author name string

P D Miller

1

1 reference

29 November 2017

R R Recker

2

1 reference

29 November 2017

J-Y Reginster

3

1 reference

29 November 2017

B J Riis

4

1 reference

29 November 2017

E Czerwinski

5

1 reference

29 November 2017

D Masanauskaite

6

1 reference

29 November 2017

A Kenwright

7

1 reference

29 November 2017

R Lorenc

8

1 reference

29 November 2017

J A Stakkestad

9

1 reference

29 November 2017

P Lakatos

10

1 reference

29 November 2017

language of work or name

English

0 references

publication date

28 September 2011

1 reference

Osteoporosis International

29 November 2017

published in

1 reference

29 November 2017

volume

23

1 reference

29 November 2017

issue

6

1 reference

29 November 2017

page(s)

1747-1756

1 reference

https://scigraph.springernature.com/pub.10.1007/s00198-011-1773-0

29 November 2017

exact match

0 references

cites work

Prevention of osteoporosis-related fractures among postmenopausal women and older men.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1773-0

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1773-0

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1773-0

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1773-0

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1773-0

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1773-0

Alendronate in the prevention of osteoporosis: 7-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1773-0

Ten years' experience with alendronate for osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1773-0

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1773-0

Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1773-0

Seven years of treatment with risedronate in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1773-0

Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1773-0

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1773-0

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1773-0

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1773-0

Patient preference in the management of postmenopausal osteoporosis with bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1773-0

Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1773-0

The Influence of Osteoporotic Fractures on Health-Related Quality of Life in Community-Dwelling Men and Women across Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1773-0

Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents

21 January 2018

1 reference

12 December 2020

Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study

1 reference

12 December 2020

Pharmacologic prevention of osteoporotic fractures.

1 reference

12 December 2020

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group

1 reference

12 December 2020

Bisphosphonate-associated adverse events.

1 reference

12 December 2020

10.1007/S00198-011-1773-0

Identifiers

DOI

1 reference

29 November 2017

1 reference